Williams v. Biomedical Advanced Research and Development Authority

CourtDistrict Court, District of Columbia
DecidedMarch 31, 2022
DocketCivil Action No. 2020-3592
StatusPublished

This text of Williams v. Biomedical Advanced Research and Development Authority (Williams v. Biomedical Advanced Research and Development Authority) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Williams v. Biomedical Advanced Research and Development Authority, (D.D.C. 2022).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

SHAKUR WILLIAMS,

Plaintiff,

v. Civil Action No. 20-3592 (FYP) BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY, et al.,

Defendants.

MEMORANDUM OPINION

Plaintiff Shakur Williams developed a COVID-19 contact-tracing app that he shared with

the United States government via email and a public website. He alleges that the information he

sent to the government was “confidential,” and that the government improperly used and

disclosed his intellectual property. He brings this suit against the Biomedical Advanced

Research and Development Authority (“BARDA”) and the United States Department of Health

and Human Services (“HHS”), alleging violations of the Federal Tort Claims Act (“FTCA”), the

Trade Secrets Act, the Sherman Antitrust Act, the Federal Trade Commission Act, the American

Inventors Protection Act, and the Fifth and Fourteenth Amendments to the United States

Constitution. Defendants BARDA and HHS move to dismiss, arguing that Plaintiff fails to state

a claim, and that this Court lacks jurisdiction. The Court agrees and will therefore grant

Defendants’ Motion.

BACKGROUND Plaintiff is an engineer who developed a COVID-19 contact-tracing app called

ConTAGV Trac. See ECF No. 6 (Amended Complaint), ¶¶ 1, 22. According to Plaintiff, his “breakthrough Pandemic 2020 preventive measure development could win a Nobel Peace Prize,”

id., ¶ 21, as “[n]o one had conceived or designed this product concept . . . by use of GPS,

Bluetooth or computer software application via mobile phone app utilization locating case

associates or people location daily,” id., ¶ 22. Williams claims that he emailed a “confidential

letter” about this “breakthrough intellectual property” to the Secretary of HHS, the Assistant

Secretary of HHS, and the U.S. Surgeon General in March 2020. Id., ¶¶ 22, 38, 46. He also

uploaded information about the app to the BARDA COVID countermeasures website in April

2020. Id., ¶ 47; see also id., ¶ 48 (stating that BARDA solicited “developments . . . from

inventors”). 1 Shortly thereafter, in April of 2020, the technology companies Apple, Inc. and

Google LLC announced that they were “partnering” to develop contact-tracing technology. Id.,

¶¶ 36, 37. Based on the timing of this announcement, Plaintiff alleges that “a leak or disclosure

of [his] confidential contact-tracing innovation was disclosed in the U.S.” Id., ¶ 32. He further

alleges that the government agencies that possessed his information negligently failed to contact

him and “conspire[d] to overlook an emergency.” Id., ¶¶ 38, 10. 2

Based on the foregoing facts, Plaintiff alleges violations of his civil rights and deprivation

of his property without due process of law, as well as “unfair and deceptive acts or practices in or

affecting commerce.” Id., ¶¶ 3, 4, 14, 15. Specifically, Williams mentions or alleges violations

1 BARDA is an office within HHS which “provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies[.]” Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness & Response (March 24, 2022), https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/default.aspx. The Court may take judicial notice of information on official government websites without transforming the motion into one for summary judgment. Dastagir v. Blinken, No. 20-cv-2286, 2021 WL 2894645, at *1 n.3 (D.D.C. July 9, 2021); Pharm. Rsch. & Mfrs. of Am. v. HHS, 43 F. Supp. 3d 28, 33 (D.D.C. 2014) (“Courts in this jurisdiction have frequently taken judicial notice of information posted on official public websites of government agencies.”). 2 Plaintiff further alleges that after he emailed his “breakthrough rapid response contact-tracing innovation” to the government, “companies, universities and public health agencies started to develop . . . the same product concept as my innovation.” Id., ¶ 7; see also id., ¶ 8 (stating that his “product concept and product design was encroached . . . without due process to me, [and] developed illegally in various states by companies and in some cases universities”). He does not, however, include any allegations about how the companies, universities, and agencies obtained information about his app.

2 of the Federal Tort Claims Act, 28 U.S.C. § 2674; the Trade Secrets Protection Act, 18 U.S.C. §

1905; the Sherman Antitrust Act, 15 U.S.C. § 2; the Federal Trade Commission Act, 15 U.S.C. §

45; the American Inventors Protection Act, 35 U.S.C. § 297(b); and the Fifth and Fourteenth

Amendments. Id. at 4, ¶¶ 8, 14–15, 38, 45, 47, 48. He seeks injunctive and declaratory relief,

compensatory damages, punitive damages, pro se fees, and litigation expenses. Id., ¶ 16. In

total, he requests between $4,200,000,000 and $4,800,000,000 in compensation. Id., ¶ 56.

On March 30, 2021, Defendants BARDA and HHS filed the instant Motion to Dismiss,

arguing that the Court lacks subject matter jurisdiction over many of Plaintiff’s claims; and that,

in any event, Plaintiff fails to state a claim. See generally ECF No. 9 (Defendants’ Motion to

Dismiss). The Motion to Dismiss is ripe for resolution.

LEGAL STANDARD To survive a motion to dismiss under Rule 12(b)(6), a complaint must “state a claim upon

which relief can be granted.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 552 (2007).

Although “detailed factual allegations” are not necessary to withstand a Rule 12(b)(6)

motion, id. at 555, “a complaint must contain sufficient factual matter, accepted as true, to ‘state

a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)

(quoting Twombly, 550 U.S. at 570).

When considering a motion to dismiss, a court must construe a complaint liberally in the

plaintiff’s favor, “treat[ing] the complaint’s factual allegations as true” and granting the plaintiff

“the benefit of all inferences that can be derived from the facts alleged.” Sparrow v. United Air

Lines, Inc., 216 F.3d 1111, 1113 (D.C. Cir. 2000) (quoting Schuler v. United States, 617 F.2d

605, 608 (D.C. Cir. 1979)); accord Kowal v. MCI Commc’ns Corp., 16 F.3d 1271, 1276 (D.C.

Cir. 1994). Although a plaintiff may survive a Rule 12(b)(6) motion even if “‘recovery is very

remote and unlikely,’” the facts alleged in the complaint “must be enough to raise a right to relief

3 above the speculative level.” Twombly, 550 U.S. at 555–56 (quoting Scheuer v. Rhodes, 416

U.S. 232, 236 (1974)).

ANALYSIS As an initial matter, Defendants have submitted a detailed Motion to Dismiss in which

they methodically discuss all of Plaintiff’s legal theories and explain why each fails on

jurisdictional grounds or fails to state a claim.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hagans v. Lavine
415 U.S. 528 (Supreme Court, 1974)
Scheuer v. Rhodes
416 U.S. 232 (Supreme Court, 1974)
Mathews v. Eldridge
424 U.S. 319 (Supreme Court, 1976)
Ruckelshaus v. Monsanto Co.
467 U.S. 986 (Supreme Court, 1984)
Neitzke v. Williams
490 U.S. 319 (Supreme Court, 1989)
Denton v. Hernandez
504 U.S. 25 (Supreme Court, 1992)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Sparrow, Victor H. v. United Airlines Inc
216 F.3d 1111 (D.C. Circuit, 2000)
Salvatore G. Crisafi v. George E. Holland
655 F.2d 1305 (D.C. Circuit, 1981)
Charles Kowal v. MCI Communications Corporation
16 F.3d 1271 (D.C. Circuit, 1994)
Trifax Corp. v. District of Columbia
53 F. Supp. 2d 20 (District of Columbia, 1999)
Moore v. Motz
437 F. Supp. 2d 88 (District of Columbia, 2006)
Colbert v. United States Postal Service
831 F. Supp. 2d 240 (District of Columbia, 2011)
Stephen A. Wannall v. Honeywell, Inc.
775 F.3d 425 (D.C. Circuit, 2014)
Francis v. Perez
256 F. Supp. 3d 1 (District of Columbia, 2017)
Kenner v. Berryhill
316 F. Supp. 3d 530 (D.C. Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Williams v. Biomedical Advanced Research and Development Authority, Counsel Stack Legal Research, https://law.counselstack.com/opinion/williams-v-biomedical-advanced-research-and-development-authority-dcd-2022.